Earnings release
Page 1
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . F 翰 森 製藥 5 HANSOH PHARMA Hansoh Pharmaceutical Group Company Limited 翰 森 製藥 集團 有限公司 ( Incorporated in the Cayman Islands with limited liability ) ( Stock Code : 3692 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30 , 2021 The board ( the “ Board ” ) of directors ( the “ Directors ” ) of Hansoh Pharmaceutical Group Company Limited ( the “ Company ” ) is pleased to announce the unaudited interim results of the Company and its subsidiaries ( collectively , the “ Group ” ) for the six months ended June 30 , 2021 , together with the comparative figures for the corresponding period in 2020 . In this announcement , “ we ” , “ us ” and “ our ” refer to the Company and where the context otherwise requires , the Group . FINANCIAL HIGHLIGHTS For the six months ended June 30 , 2021 , the Group recorded the following unaudited results : Revenue was approximately RMB4,402 million , representing an increase of approximately 10.6 % compared with the corresponding period of the previous year ; R & D expenditure was approximately RMB687 million , representing an increase of approximately 44.2 % compared with the corresponding period of the previous year , and accounted for approximately 15.6 % of the revenue ; Net profit was approximately RMB1,291 million , representing an increase of approximately 5.6 % compared with the corresponding period of the previous year ; Basic earnings per share was approximately RMB0.22 , representing an increase of approximately 4.1 % compared with the corresponding period of the previous year ; Sales of innovative drugs accounted for approximately 28.5 % of the Group's revenue ; sales of innovative drugs accounted for approximately 18.9 % of the Group's revenue for the corresponding period of the previous year . 1